- Home
- MODD vs PEPG Comparison
MODD vs PEPG Comparison
Compare MODD & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- PEPG
- Stock Information
- Founded
- MODD 1998
- PEPG 2018
- Country
- MODD United States
- PEPG United States
- Employees
- MODD N/A
- PEPG N/A
- Industry
- MODD Industrial Specialties
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- PEPG Health Care
- Exchange
- MODD Nasdaq
- PEPG Nasdaq
- Market Cap
- MODD 46.3M
- PEPG 52.4M
- IPO Year
- MODD N/A
- PEPG 2022
- Fundamental
- Price
- MODD $0.79
- PEPG $1.40
- Analyst Decision
- MODD
- PEPG Buy
- Analyst Count
- MODD 0
- PEPG 3
- Target Price
- MODD N/A
- PEPG $7.67
- AVG Volume (30 Days)
- MODD 94.9K
- PEPG 169.8K
- Earning Date
- MODD 06-20-2025
- PEPG 08-07-2025
- Dividend Yield
- MODD N/A
- PEPG N/A
- EPS Growth
- MODD N/A
- PEPG N/A
- EPS
- MODD N/A
- PEPG N/A
- Revenue
- MODD N/A
- PEPG N/A
- Revenue This Year
- MODD N/A
- PEPG N/A
- Revenue Next Year
- MODD N/A
- PEPG N/A
- P/E Ratio
- MODD N/A
- PEPG N/A
- Revenue Growth
- MODD N/A
- PEPG N/A
- 52 Week Low
- MODD $0.68
- PEPG $0.88
- 52 Week High
- MODD $2.65
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- MODD 44.55
- PEPG 48.28
- Support Level
- MODD $0.77
- PEPG $1.37
- Resistance Level
- MODD $0.88
- PEPG $1.49
- Average True Range (ATR)
- MODD 0.08
- PEPG 0.09
- MACD
- MODD 0.00
- PEPG -0.00
- Stochastic Oscillator
- MODD 49.48
- PEPG 38.46
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.